We continue to monitor COVID-19 cases in our area and providers will notify you if there are scheduling changes. Please continue to call your providers with health concerns. We are providing in-person care and telemedicine appointments.
Learn about our expanded patient care options and visitor guidelines.
General Information | Self-Checker | Donate and Lend Support | Staff Appreciation | Get Email Alerts
Enter the last name, specialty or keyword for your search below.
The Linda Smith-Resar Lab primarily investigates hematologic malignancy and molecular mechanisms that lead to cancer as well as sickle cell anemia. Recent studies suggest that education is an important and effective component of a patient blood management program and that computerized provider order entry algorithms may serve to maintain compliance with evidence-based transfusion guidelines. Another recent study indicated that colonic epithelial cells undergo metabolic reprogramming during their evolution to colorectal cancer, and the distinct metabolites could serve as diagnostic tools or potential targets in therapy or primary prevention.
Research in the Mary Catherine Beach Lab focuses on physician mindfulness and the patient-provider relationship and how such factors impact health care quality. Current research involves investigating the theoretical foundations of respect, as well as the impact of physician attitudes and communication on patients in the primary care setting, with a specific focus on HIV, substance abuse and sickle cell disease patients. We also explore issues such as patients’ rights, mental health parity, human subject protection, genetic discrimination, human cloning and stem cell research.
The lab studies the development of blood vessels in the eye and how they change in diseases like retinopathy of prematurity, sickle cell and diabetic retinopathies, and age-related macular degeneration (AMD). The ultimate goal of the lab is to develop a new generation of therapies that, when delivered to the eye, allow the tissues of the eye to essentially treat themselves only when needed. The goal is to have the tissues generate their own therapeutics when needed, and stop production when the condition is resolved. These therapies will help reduce the need for repeated treatment and provide focused therapy, rather than treating the body with chemicals.
The Rakhi Naik Lab studies sickle cell disease. We focus on complications related to the disease, including chronic kidney disease and venous thromboembolism. By defining the risks and factors for diseases related to the sickle cell trait, we hope to improve genetic counseling and screening and treatment recommendations. Other research in the lab examines the epidemiology and unique mechanisms of thrombosis in patients with hemoglobin disorders. Specifically, we are trying to identify mechanisms of hypercoagulability and develop treatments for patients with hemoglobinopathies.
Work in the Sophie Lanzkron Lab is focused on understanding the barriers to care for adults with sickle cell disease. Our research has shown that despite the approval of hydroxyurea treatment predicted to decrease hospitalizations for sickle cell disease patients' the cost of care has increased significantly in recent years. Research is ongoing to identify the factors that limit access to care for this population.
Language Assistance Available:
© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
